Arena Pharmaceuticals Inc ARNA:NASDAQ

Last Price$90.48NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.53(0.58%)
Bid (Size)$90.40 (3)
Ask (Size)$92.00 (1)
Day Low / High$90.45 - 91.38
Volume1.8 M
  • Latest Stories
  • Commentary and Analysis
Cantor Fitzgerald Downgrades Arena Pharmaceuticals to Neutral From Overweight, Adjusts Price Target to $100 From $93
5:06AM ET 12/21/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of hold and price targets ranging from $80 to $120, according to analysts polled by Capital IQ. (MT...

Arena's PT Hiked to $100 by RBC in Line With Pfizer's Proposed Bid; Downgraded to Sector Perform as no Deal Hurdles Seen
3:37PM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals' (ARNA) price target has been raised to $100 from $76 by RBC Capital on Tuesday in line with Pfizer's (PFE) proposed acquisition...

Citigroup Downgrades Arena Pharmaceuticals to Neutral From Buy, Adjusts Price Target to $100 From $101
10:03AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average outperform rating and a price target range of $80 to $120, according to analysts polled by Capital IQ. (MT...

--Needham Downgrades Arena Pharmaceuticals to Hold From Buy, Drops $80 Price Target
9:15AM ET 12/14/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Wells Fargo Downgrades Arena Pharmaceuticals to Equal Weight From Overweight, Lifts Price Target to $100 From $71
9:12AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of Outperform and price targets ranging from $80 to $120, according to analysts polled by Capital IQ....

Credit Suisse Downgrades Arena Pharmaceuticals to Neutral from Outperform Following News of Sale to Pfizer, Raises PT to $100 from $98
9:12AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of outperform and price targets ranging from $80 to $120, according to analysts polled by Capital IQ....

RBC Downgrades Arena Pharmaceuticals to Sector Perform From Outperform, Lifts Price Target to $100 From $76 Amid Pfizer Deal
9:09AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $80 to...

JMP Securities Downgrades Arena Pharmaceuticals to Market Perform From Market Outperform
6:53AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of outperform and price targets ranging from $71 to $120, according to analysts polled by Capital IQ....

SVB Leerink Downgrades Arena Pharmaceuticals to Market Perform From Outperform; Price Target is $100
6:52AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of outperform and price targets ranging from $71 to $120, according to analysts polled by Capital IQ....

Jefferies Downgrades Arena Pharmaceuticals to Hold From Buy, Price Target is $100
6:50AM ET 12/14/2021 MT Newswires

Arena Pharmaceuticals (ARNA) has an average rating of outperform and price targets ranging from $71 to $120, according to analysts polled by Capital IQ....